ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near New York, NY, USA:

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)

Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive ...

Enrolling
Triple Negative Breast Cancer
Drug: Merck 3475 Pembrolizumab
Radiation: Intraoperative radiation therapy (IORT)

Phase 1

Eileen Connolly

New York, New York, United States and 2 other locations

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer and triple...

Active, not recruiting
Metastatic Breast Cancer
Triple Negative Breast Cancer
Drug: PMD-026

Phase 1

Phoenix Molecular Designs

New York, New York, United States and 8 other locations

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 9 other locations

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

New York, New York, United States and 44 other locations

pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread ...

Enrolling
Anatomic Stage IV Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Other: Questionnaire Administration
Biological: Retifanlimab

Phase 2

Mridula George, MD

New Brunswick, New Jersey, United States and 1 other location

inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study...

Active, not recruiting
Breast Cancer
Biological: Durvalumab
Biological: PVX-410

Phase 1

Mass General Brigham
Mass General Brigham

New York, New York, United States and 4 other locations

the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Enzalutamide
Behavioral: assessment

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 11 other locations

of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC).Study close to a...

Active, not recruiting
Breast Cancer
Drug: Everolimus
Drug: Carboplatin

Phase 2

amy tiersten

New York, New York, United States and 2 other locations

This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms bas...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Inavolisib
Drug: Talazoparib

Phase 2

Bryan Schneider, MD

Berkeley Heights, New Jersey, United States and 12 other locations

a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast...

Active, not recruiting
Breast Cancer
Drug: Rucaparib
Radiation: Radiotherapy

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems